- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02774551
Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength
Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength in Esophageal Cancer Survivors
This intervention study will be conducted on patients included in a nationwide and prospective cohort, The Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR). The OSCAR includes patients operated on for oesophageal cancer in Sweden between 2013-2018, identified through pathology departments and included in the cohort 1 year after surgery. A comprehensive interview is conducted by a research nurse during a home visit using patient reported outcomes on several HRQOL, psychosocial, emotional and nutritional aspects. Regular follow-ups are carried out at 1½, 2, 2½, 3, 4 and 5 years postoperatively.
All patients within OSCAR are invited to the intervention trial. Half of the eligible patients will be randomised to intervention and half to standard care (control group) by means of block randomisation method. The intervention group will be encouraged to adhere to a physical activity regimen of 150 minutes of weekly minimum intensity activities and 5 simple strength training exercises twice a week as instructed by the research nurse. The control group will follow their routine daily physical activity. HRQOL measures, height and weight, body composition, muscle strength, functional mobility and strength, and dietary intake are assessed before and after the intervention. Compliance will be ensured by means of a daily physical activity dairy and a weekly follow up on telephone with all patients.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Stockholm, Ruotsi
- Surgical cares sciences, Karolinksa Institutet
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- All patients from the nationwide prospective cohort the Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR) with willingness to participate
Exclusion Criteria:
- Current malignancies or co-morbidities, psychological or social conditions that prevent participation
- Patients with pacemakers; cochlear or other electrical implants cannot be screened using the bio-impedance scale for safety reasons
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Physical activity intervention group
The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g.
walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse.
The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
|
150 minutes of minimum intensity activity during a week (e.g.
walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
|
Ei väliintuloa: Standard care control group
Patients follow their routine daily physical activity.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of participants with treatment related increase in muscle mass as assessed by a bio-impedance body composition scale.
Aikaikkuna: At baseline and after the 12 weeks intervention/control programme.
|
The main outcome measure will be increase in skeletal muscle mass using a bio-impedance analysis portable monitor.
Changes occurring during the period just before and just after the 12-weeks intervention programme, or standard of care in the comparison group, will be compared between the intervention group.
|
At baseline and after the 12 weeks intervention/control programme.
|
Number of participants with treatment related increase in muscle strength as assessed by a hand grip dynamometer and chair stand test.
Aikaikkuna: At baseline and after the 12 weeks intervention/control programme.
|
The main outcome measure will be increase in skeletal muscle strength using a handgrip dynamometer and 30 second sit stand test.
Changes occurring during the period just before and just after the 12-weeks intervention programme, or standard of care in the comparison group, will be compared between the intervention group.
|
At baseline and after the 12 weeks intervention/control programme.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of participants with improvement in physical function scale of health related quality of life as assessed from the questionnaire - European Organization for Research and Treatment of Cancer (EORTC); Quality of Life Questionnaire (QLQ) - C30.
Aikaikkuna: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the physical function scale of HRQOL using EORTC QLQ-C30 questionnaires before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
Number of participants with improvement in fatigue scale of health related quality of life as assessed from the questionnaire - EORTC QLQ-FA13.
Aikaikkuna: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the fatigue scale of HRQOL using EORTC fatigue questionnaire QLQ-FA13 before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
Number of participants with improvement in appetite loss function of health related quality of life as assessed from the oesophageal disease specific module - EORTC QLQ-OG25.
Aikaikkuna: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the appetite loss function of HRQOL using EORTC QLQ-OG25 questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
Number of participants with improvement in eating difficulties scale of health related quality of life as assessed from the cachexia module of EORTC - QLQ-CAX24.
Aikaikkuna: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the eating difficulties scale of HRQOL using EORTC QLQ-CAX24 questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
Number of participants with improvement in psycho social issues as assessed from the questionnaire - Hospital Anxiety and Depression Scale (HADS).
Aikaikkuna: At baseline and after the12 weeks intervention/control programme.
|
This secondary outcome will assess the psychosocial issues using HADS questionnaire before and after the intervention.
|
At baseline and after the12 weeks intervention/control programme.
|
Number of participants with improvement in physical activity level measured using the international physical activity questionnaire (IPAQ).
Aikaikkuna: At baseline and after the 12 weeks intervention/control programme.
|
This secondary outcome shall include changes in the total physical activity level measured using the international physical activity questionnaire (IPAQ) before and after the intervention.
|
At baseline and after the 12 weeks intervention/control programme.
|
Number of participants with improvement in dietary intake measured using 3 day food diary.
Aikaikkuna: Just before (baseline) and just after (final follow up) the 12 weeks intervention programme.
|
This secondary outcome shall include changes in dietary intake measured using food dairy measured thrice a week: two weekdays and 1 weekend day before and after the intervention.
|
Just before (baseline) and just after (final follow up) the 12 weeks intervention programme.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Pernilla Lagergren, Professor, Karolinska Institutet
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- PA study
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Ruokatorven syöpä
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)ValmisLymfaödeema | Perioperatiiviset/postoperatiiviset komplikaatiot | Vaiheen II Vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Stage IVA Vulvar Cancer AJCC v7 | Vaihe IA Vulvar Cancer AJCC v7 | Vaihe IB Vulvar Cancer AJCC v7 | Vaihe...Yhdysvallat
-
Fore BiotherapeuticsRekrytointiCancer sisältää BRAF-muutoksiaYhdysvallat, Saksa, Espanja, Yhdistynyt kuningaskunta, Ranska, Korean tasavalta, Italia, Ruotsi, Kanada
-
Samsung Medical CenterValmisHER2-positiivinen Refractory Advanced CancerKorean tasavalta
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Aktiivinen, ei rekrytointiVaiheen III vulvar Cancer AJCC v7 | Vaihe IIIA Vulvar Cancer AJCC v7 | Vaihe IIIB Vulvar Cancer AJCC v7 | Vaihe IIIC Vulvar Cancer AJCC v7 | Epäsuoran levyepiteelisyöpä | Stage IVA Vulvar Cancer AJCC v7Yhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrytointiVaiheen II Vulvar Cancer AJCC v8 | Vaiheen IIIC vulvar Cancer AJCC v8 | Stage IVA Vulvar Cancer AJCC v8 | Kolmannen vaiheen ulkosynnyttäjäsyöpä AJCC v8 | Vaihe IIIA Vulvar Cancer AJCC v8 | Vaihe IIIB Vulvar Cancer AJCC v8Yhdysvallat
-
University of UtahNational Cancer Institute (NCI)RekrytointiVäsymys | Istuva elämäntapa | Metastaattinen eturauhassyöpä | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8 | Stage IVB Eturauhassyöpä AJCC (American Joint Committee on Cancer) v8Yhdysvallat
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...ValmisTutki kiinalaisia naisia, jotka eivät ole noudattaneet American Cancer Societyn mammografiaseulontaohjeitaYhdysvallat
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ValmisOhutsuolen adenokarsinooma | Vaihe III ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIA ohutsuolen adenokarsinooma AJCC v8 | Vaihe IIIB ohutsuolen adenokarsinooma AJCC v8 | IV vaiheen ohutsuolen adenokarsinooma AJCC v8 | Vater-adenokarsinooman ampulla | Vaiheen III ampulla Vater Cancer AJCC v8 | Vaiheen... ja muut ehdotYhdysvallat
-
Centre Francois BaclesseLigue contre le cancer, FranceRekrytointiPitkäaikaiset syövän sivuvaikutukset | Tukihoito syövän hoidossa | Cancer Survivorship Care Plan | Edistynyt sairaanhoitaja | Lantion gynekologinen syöpäRanska
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrytointiMetastaattinen keuhkojen ei-pienisolusyöpä | Tulenkestävä keuhkojen ei-pienisolusyöpä | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Vaihe IVB keuhkosyöpä AJCC v8Yhdysvallat
Kliiniset tutkimukset Physical activity intervention group
-
University of MichiganValmis
-
Binghamton UniversityLehigh University; Ascension HealthEi vielä rekrytointiaLihavuus | Liikunta | Itsetehokkuus | Online-interventio | Kiihtyvyysmittarit
-
University of PittsburghNational Center for Advancing Translational Sciences (NCATS)ValmisYlipaino ja lihavuus | Istuva käyttäytyminen | Kardiovaskulaarinen riskitekijä | PrediabetesYhdysvallat
-
University of PittsburghValmisYlipaino ja lihavuus | Istuva käyttäytyminen | Kardiovaskulaarinen riskitekijä | PrediabetesYhdysvallat
-
Centre Hospitalier Universitaire de Saint EtienneNational Cancer Institute, FranceValmis
-
University of WashingtonValmis
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)Valmis
-
The University of Texas Health Science Center,...Texas Neurological Society Research Grant-2020Valmis
-
IVI BilbaoInstituto Valenciano de Infertilidad, IVI VALENCIAValmis
-
Ankara Yildirim Beyazıt UniversityTuntematonVäsymys | Liikunta | NukkuaTurkki